IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN REPATENT OF

Caligiuri, M.D., Michael A. et al.

U.S. PATENT NO: 7,306,801

ISSUED: December 11, 2007

FOR: Methods of Therapy for Cancers Characterized by Overexpression of

The HER2 Receptor Protein

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Request for Certificate of Correction under CFR § 1.323

Sir:

Pursuant to 37 CFR 1.323, it is hereby respectfully requested that a Certificate of Correction be issued for United States Patent 7,306,801 containing the corrections set forth on the appended Form PTO 1050.

The error is believed to be attributable to Applicants.

Attached is Form PTO 1050 being suitable for printing.

Since the above error is ascribable to the patentees, please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$100 for payment of the fee required by 37 CFR §1.20.

The Commissioner is hereby authorized to charge the above-mentioned \$100 fee and any additional fees which may be required to Deposit Account No. 19-0134 in the name of Novartis.

Please send the Certificate of Correction to the address currently associated with Customer No. 001095, viz:

Novartis Pharmaceuticals Corporation One Health Plaza, Bldg. 101 East Hanover, NJ 07936

Novartis Pharmaceuticals Corporation One Health Plaza, Bldg. 101 East Hanover, NJ 07936 (862) 778-7898

Date: May 25, 2011

Encls.: Form PTO 1050

Respectfully submitted,

Lydia McNally

Attorney for Applicant

Reg. No. 36,214

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

7,306,801

DATED:

December 11, 2007

INVENTOR(S) :

Caligiuri, M.D., Michael A. et al.

It is certified that there is/are an error(s) in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please add the following language to column 1, line 12, at the end of the paragraph:

--This invention was made with government support under CA31946 and CA44691 as awarded by the National Institutes of Health. The government has certain rights in the invention.--

MAILING ADDRESS OF SENDER:

PATENT NO. 7306801

Lydia McNally
Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-7898

FORM **PTO-1050**